The University of the Sunshine Coast leads rollout of critical vaccine for koalas
USC is leading a Phase 3 rollout of a koala chlamydia vaccine that has been developed collaboratively over many years with many partners, including VIDO.
New funding will help predict SARS-CoV-2 variants and protect vulnerable populations
VIDO scientist Dr. Alyson Kelvin was awarded close to half a million dollars to assess COVID-19 vaccine efficacy including against virus variants in vulnerable populations.
Alumni Ron and Jane Graham’s $5.9M gift assists vaccine research, Huskie Athletics, engineering and education students at USask
The University of Saskatchewan’s most generous alumni, Ron and Jane Graham, are supporting the Vaccine and Infectious Disease Organization with a $1M donation.
Three USask researchers become fellows in the Canadian Academy of Health Sciences
Dr. Volker Gerdts, VIDO Director and CEO, has been inducted as fellows to the Canadian Academy of Health Sciences.
Saskatoon couple donates $1 million to VIDO to enhance ground-breaking vaccine research
Malcolm and Marilyn Leggett have donated $1 million to help establish VIDO as Canada’s Centre for Pandemic Research and advance its ground-breaking research on infectious diseases, including COVID-19.
Infectious disease research bolstered by Hospitals of Regina Foundation
To help protect Saskatchewan residents from emerging disease threats, Hospitals of Regina Foundation has invested $150,000 to help establish Canada’s Centre for Pandemic Research at USask's Vaccine and Infectious Disease Organization.
VIDO research provides insight into the immune response and possible long-term health impacts associated with COVID-19
One of the newest scientists at the University of Saskatchewan’s Vaccine and Infectious Disease Organization has published new research on potential lasting effects of COVID-19.
USask’s VIDO announces positive Phase 1 results for COVAC-2
The Vaccine and Infectious Disease Organization at the University of Saskatchewan announced positive interim results from their Phase 1 clinical trial for COVAC-2, VIDO’s COVID-19 subunit vaccine candidate.
Sask.-based research offers hope in unsettling times
Uncertain times require robust social sciences and humanities analysis, and leadership from scholars to discuss complex issues with the public.
Saskatchewan Blue Cross invests $150K to help establish USask’s VIDO as Canada’s Centre for Pandemic Research
The Vaccine and Infectious Disease Organization at the University of Saskatchewan is one step closer to establishing its Centre for Pandemic Research, thanks to a $150,000 donation from Saskatchewan Blue Cross.